carmustine has been researched along with Spinal Cord Diseases in 1 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
Spinal Cord Diseases: Pathologic conditions which feature SPINAL CORD damage or dysfunction, including disorders involving the meninges and perimeningeal spaces surrounding the spinal cord. Traumatic injuries, vascular diseases, infections, and inflammatory/autoimmune processes may affect the spinal cord.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The syndrome of retinal vascular occlusion, optic neuropathy, and myelopathy is associated with the high-dose chemotherapeutic agents carmustine and cisplatin." | 7.70 | Bilateral blindness and lumbosacral myelopathy associated with high-dose carmustine and cisplatin therapy. ( Arnold, AC; Glasgow, BJ; Vinters, HV; Wang, MY, 2000) |
| "The syndrome of retinal vascular occlusion, optic neuropathy, and myelopathy is associated with the high-dose chemotherapeutic agents carmustine and cisplatin." | 3.70 | Bilateral blindness and lumbosacral myelopathy associated with high-dose carmustine and cisplatin therapy. ( Arnold, AC; Glasgow, BJ; Vinters, HV; Wang, MY, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, MY | 1 |
| Arnold, AC | 1 |
| Vinters, HV | 1 |
| Glasgow, BJ | 1 |
1 other study available for carmustine and Spinal Cord Diseases
| Article | Year |
|---|---|
Bilateral blindness and lumbosacral myelopathy associated with high-dose carmustine and cisplatin therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blindness; Breast Neoplasms; Carcinoma, Ductal, Brea | 2000 |